Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice

Hong Wu Shen, Aiming Yu

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Desipramine (DMI), a CYP2D6 probe, was used as a model drug to test whether CYP2D6-humanized (Tg-CYP2D6) and wild-type control mice could be used as preclinical animal models to identify the effects of CYP2D6 genotype/phenotype on drug metabolic profiles. After the analyses by liquid chromatography coupled with tandem mass spectrometry, DMI biotransformations were compared in Tg-CYP2D6 and wild-type mouse liver microsomes (MLM), and in human CYP2D6 extensive and poor metabolizer liver microsomes. Furthermore, urinary DMI metabolic profiles in Tg-CYP2D6 and wild-type mice were evaluated. Three metabolites, 2-hydroxyl-, 10-hydroxyl, and N-desmethyl-desipramine were identified in the incubations of DMI with both wild-type and Tg-CYP2D6 MLM, as well as in human CYP2D6 extensive metabolizer liver microsomes. Three additional metabolites were found in mouse urine samples, and their chemical structures were elucidated. Although the ratio of individual metabolites produced in Tg-CYP2D6 MLM was closer to that in human CYP2D6 extensive metabolizer liver microsomes, the urinary DMI metabolic profiles did not show much difference between wildtype and Tg-CYP2D6 mice. The results suggest that other mouse enzymes have significant contribution to DMI metabolism.

Original languageEnglish (US)
Pages (from-to)234-241
Number of pages8
JournalDrug Metabolism Letters
Volume3
Issue number4
DOIs
StatePublished - Dec 2009
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP2D6
Desipramine
Metabolome
Liver Microsomes
Liver
Metabolites
Hydroxyl Radical
Liquid chromatography
Biotransformation
Tandem Mass Spectrometry
Metabolism
Liquid Chromatography
Pharmaceutical Preparations
Mass spectrometry
Animals
Animal Models

Keywords

  • CYP2D6
  • Desipramine
  • Mass spectrometry
  • Metabolism
  • Mouse
  • Transgenic

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Pharmacology (medical)
  • Pharmaceutical Science

Cite this

Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice. / Shen, Hong Wu; Yu, Aiming.

In: Drug Metabolism Letters, Vol. 3, No. 4, 12.2009, p. 234-241.

Research output: Contribution to journalArticle

@article{a20dae9f17fa4c2e8e333efbdf0dbba8,
title = "Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice",
abstract = "Desipramine (DMI), a CYP2D6 probe, was used as a model drug to test whether CYP2D6-humanized (Tg-CYP2D6) and wild-type control mice could be used as preclinical animal models to identify the effects of CYP2D6 genotype/phenotype on drug metabolic profiles. After the analyses by liquid chromatography coupled with tandem mass spectrometry, DMI biotransformations were compared in Tg-CYP2D6 and wild-type mouse liver microsomes (MLM), and in human CYP2D6 extensive and poor metabolizer liver microsomes. Furthermore, urinary DMI metabolic profiles in Tg-CYP2D6 and wild-type mice were evaluated. Three metabolites, 2-hydroxyl-, 10-hydroxyl, and N-desmethyl-desipramine were identified in the incubations of DMI with both wild-type and Tg-CYP2D6 MLM, as well as in human CYP2D6 extensive metabolizer liver microsomes. Three additional metabolites were found in mouse urine samples, and their chemical structures were elucidated. Although the ratio of individual metabolites produced in Tg-CYP2D6 MLM was closer to that in human CYP2D6 extensive metabolizer liver microsomes, the urinary DMI metabolic profiles did not show much difference between wildtype and Tg-CYP2D6 mice. The results suggest that other mouse enzymes have significant contribution to DMI metabolism.",
keywords = "CYP2D6, Desipramine, Mass spectrometry, Metabolism, Mouse, Transgenic",
author = "Shen, {Hong Wu} and Aiming Yu",
year = "2009",
month = "12",
doi = "10.2174/187231209790218118",
language = "English (US)",
volume = "3",
pages = "234--241",
journal = "Drug Metabolism Letters",
issn = "1872-3128",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Difference in desipramine metabolic profile between wild-type and CYP2D6-humanized mice

AU - Shen, Hong Wu

AU - Yu, Aiming

PY - 2009/12

Y1 - 2009/12

N2 - Desipramine (DMI), a CYP2D6 probe, was used as a model drug to test whether CYP2D6-humanized (Tg-CYP2D6) and wild-type control mice could be used as preclinical animal models to identify the effects of CYP2D6 genotype/phenotype on drug metabolic profiles. After the analyses by liquid chromatography coupled with tandem mass spectrometry, DMI biotransformations were compared in Tg-CYP2D6 and wild-type mouse liver microsomes (MLM), and in human CYP2D6 extensive and poor metabolizer liver microsomes. Furthermore, urinary DMI metabolic profiles in Tg-CYP2D6 and wild-type mice were evaluated. Three metabolites, 2-hydroxyl-, 10-hydroxyl, and N-desmethyl-desipramine were identified in the incubations of DMI with both wild-type and Tg-CYP2D6 MLM, as well as in human CYP2D6 extensive metabolizer liver microsomes. Three additional metabolites were found in mouse urine samples, and their chemical structures were elucidated. Although the ratio of individual metabolites produced in Tg-CYP2D6 MLM was closer to that in human CYP2D6 extensive metabolizer liver microsomes, the urinary DMI metabolic profiles did not show much difference between wildtype and Tg-CYP2D6 mice. The results suggest that other mouse enzymes have significant contribution to DMI metabolism.

AB - Desipramine (DMI), a CYP2D6 probe, was used as a model drug to test whether CYP2D6-humanized (Tg-CYP2D6) and wild-type control mice could be used as preclinical animal models to identify the effects of CYP2D6 genotype/phenotype on drug metabolic profiles. After the analyses by liquid chromatography coupled with tandem mass spectrometry, DMI biotransformations were compared in Tg-CYP2D6 and wild-type mouse liver microsomes (MLM), and in human CYP2D6 extensive and poor metabolizer liver microsomes. Furthermore, urinary DMI metabolic profiles in Tg-CYP2D6 and wild-type mice were evaluated. Three metabolites, 2-hydroxyl-, 10-hydroxyl, and N-desmethyl-desipramine were identified in the incubations of DMI with both wild-type and Tg-CYP2D6 MLM, as well as in human CYP2D6 extensive metabolizer liver microsomes. Three additional metabolites were found in mouse urine samples, and their chemical structures were elucidated. Although the ratio of individual metabolites produced in Tg-CYP2D6 MLM was closer to that in human CYP2D6 extensive metabolizer liver microsomes, the urinary DMI metabolic profiles did not show much difference between wildtype and Tg-CYP2D6 mice. The results suggest that other mouse enzymes have significant contribution to DMI metabolism.

KW - CYP2D6

KW - Desipramine

KW - Mass spectrometry

KW - Metabolism

KW - Mouse

KW - Transgenic

UR - http://www.scopus.com/inward/record.url?scp=74749087294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749087294&partnerID=8YFLogxK

U2 - 10.2174/187231209790218118

DO - 10.2174/187231209790218118

M3 - Article

C2 - 19995332

AN - SCOPUS:74749087294

VL - 3

SP - 234

EP - 241

JO - Drug Metabolism Letters

JF - Drug Metabolism Letters

SN - 1872-3128

IS - 4

ER -